Loading
Led PATHFINDER, the first prospective study of a multi-cancer blood test in practice, and the PROSPECT rectal cancer trial.
Deborah Schrag was principal investigator of PATHFINDER, the first prospective study to return Galleri multi-cancer early detection results to participants and their doctors, which showed a cancer signal in about 1% of people and a positive predictive value near 40%, and of PROSPECT, the Alliance trial showing FOLFOX can replace pelvic radiotherapy for many rectal cancers. She chairs medicine at MSKCC and leads pragmatic outcomes research.
Shares PATHFINDER 2, PATHFINDER: the first prospective test of a multi-cancer blood test in people without symptoms, Galleri, NHS-Galleri and the tags early-detection, mced.
Shares PATHFINDER 2, Galleri, NHS-Galleri, Multi-cancer early detection (MCED).
Shares Multi-cancer early detection (MCED), ctDNA tests roadmap: from a curiosity in plasma to blood tests that decide treatment and the tags early-detection, mced.
Shares PATHFINDER 2, Galleri, NHS-Galleri, Multi-cancer early detection (MCED).
Shares PATHFINDER 2, Galleri, NHS-Galleri, Multi-cancer early detection (MCED).
Shares Galleri, NHS-Galleri, Multi-cancer early detection (MCED), ctDNA tests roadmap: from a curiosity in plasma to blood tests that decide treatment.
Shares PATHFINDER 2, Galleri, NHS-Galleri, Multi-cancer early detection (MCED).
Shares PATHFINDER 2, Galleri, NHS-Galleri, Multi-cancer early detection (MCED).